Compare Ginkgo Bioworks Holdings Inc (DNA) vs Sea Limited (SE) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.

The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.

Sea Limited (SE) trades at $94.66, down 1.94% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamental progress with revenue growing from $12.4B in 2022 to $22.9B in 2025 and achieving profitability, though recent Q4 2025 earnings missed expectations. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $153.67 consensus price target, representing significant upside potential from current levels.

Sea presents a compelling growth story with expanding profitability and strong e-commerce momentum, though execution risks and competitive pressures persist. The stock's current valuation at 36.55x P/E reflects growth expectations, while technical weakness suggests potential near-term consolidation. Institutional confidence remains high despite recent insider selling activity.